VitaLonga

Clinical trial · Supplements / medicine · 19 Nov 2026

In two phase 3 trials, retatrutide lined up with large weight loss and less knee pain, and joint damage was not shown to stop

Source: Northwestern University

What the research found

Northwestern University described two phase 3 trials, published in the New England Journal of Medicine on 8 November 2026, in adults with obesity and painful knee osteoarthritis. Together the trials included more than 1,000 participants. At the highest dose of retatrutide, an experimental weekly injection, average weight loss was about 25 percent of body weight. Across the two trials, about two-thirds of people on retatrutide reported at least a 50 percent drop in knee pain, compared with 38 percent on placebo. Blood pressure, blood lipids, and body-wide inflammation markers also moved down. The trials do not show that the drug slows joint damage or reduces later knee replacement. People who already needed a replacement were excluded, and people without extra weight were not studied. Retatrutide, developed by Eli Lilly, acts on three hormone receptors rather than the one or two used by semaglutide and tirzepatide. Lilly scientists were co-authors. Thomas Schnitzer, the corresponding author, still points to eating and activity changes as the starting point, including because appetite-suppressing drugs can come with muscle loss that knees rely on. This is an experimental medicine, not a supplement, and it is not an instruction to start or swap any prescription. Not medical advice.

Evidence level: Clinical trial. This is among the stronger kinds of evidence, but one study rarely settles a question.

Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.

Read the original at Northwestern University

More supplements / medicine news